Target intelligence / Profile preview

Ferriprotoporphyrin IX (FP-IX) (FP-IX)

Target
FP-IX
Molecular classification
Metalloporphyrin, Porphyrin, Metabolic byproduct
01

Overview

Ferriprotoporphyrin IX (FP-IX), commonly known as free heme, is a potent toxin produced by Plasmodium falciparum during its consumption of host hemoglobin within red blood cells (Hempelmann, 2007, Parasitology Research). Because the parasite lacks a heme-degrading enzyme like heme oxygenase, it must detoxify the released FP-IX by sequestering it into an insoluble crystalline polymer called hemozoin, or malaria pigment (Sullivan, 2002, International Journal for Parasitology). This detoxification pathway is essential for parasite survival, as free heme can generate reactive oxygen species and disrupt cellular membranes (Egan, 2008, Journal of Inorganic Biochemistry). Many classic antimalarial drugs, particularly the quinolines like chloroquine and quinine, target this process by binding directly to free heme (PubChem, CID 5460340). This binding prevents the formation of hemozoin, causing toxic heme-drug complexes to accumulate within the parasite's digestive vacuole. The resulting oxidative stress and membrane damage ultimately lead to the death of the parasite. Resistance to these drugs often arises from mutations in the Plasmodium falciparum chloroquine resistance transporter (PfCRT), which pumps the drugs out of the digestive vacuole (Fidock et al., 2000, Molecular Cell). Understanding the interaction between FP-IX and antimalarials remains a cornerstone of malaria drug discovery and resistance monitoring.

Other names
Free hemeHematinHemeProtoporphyrin IX iron(III)Ferriheme
02

Mechanism of action

Inhibition of heme biocrystallization into hemozoin, leading to the accumulation of toxic free heme and heme-drug complexes that cause membrane damage and parasite death.

03

Biological functions

Heme detoxificationBiocrystallizationOxidative stress induction
04

Disease associations

MalariaInfection
05

Safety considerations

Drug resistance via parasite transporter mutations (e.g., PfCRT)Potential for oxidative damageLimited efficacy against non-erythrocytic stages
06

Interacting drugs

Chloroquine

7 more in the full profile.

07

Biomarkers

Hemozoin (malaria pigment) levelsParasite clearance ratePfCRT mutation status

Beyond the preview

Go deeper on Ferriprotoporphyrin IX (FP-IX) (FP-IX).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ferriprotoporphyrin IX (FP-IX) (FP-IX).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call